What’s new in cardiac imaging?

  • Ernst E. Van Der Wall
Part of the Developments in Cardiovascular Medicine book series (DICM, volume 133)


Nuclear cardiology is frequently used to detect, localize, and size the extent of damage to myocardial tissue. In combination with exercise or pharmacologic stress, it can also detect residual myocardial ischemia and thereby determine prognosis. New radionuclides have emerged that allow greater accuracy and feasibility for distinguishing viable from irreversible injury in patients with myocardial infarction, particularly after reperfusion therapy. A variety of new imaging approaches have emerged that employ both gamma- and positronemitting tracers. This introductory chapter will briefly address the most important new cardiac imaging agents and the latest developments with the currently used tracers. Most of these attainments will be extensively discussed in the following chapters of this book.


Positron Emission Tomography Nuclear Cardiology Perfusion Defect Antimyosin Antibody Antimyosin Uptake 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kiat H, Berman DS, Maddahi J et al. Late reversibility of tomographic myocardial thallium-201 defects: an accurate marker of myocardial viability. J Am Coll Cardiol2 1988; 12: 1456–63.PubMedCrossRefGoogle Scholar
  2. 2.
    Dilsizian V, Rocco T, Freedman NMT, Leon MB, Bonow RO. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med 1990; 323: 141–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Verzijlbergen JF, Cramer MJ, Niemeyer MG, Ascoop CAPL, Van der Wall EE, Pauwels EKJ. ECG—gated and static technetium-99m-SESTAMIBI planar myocardial perfusion imaging: a comparison with thallium-201 and study of observer variabilities. Am J Physiol Imaging 1990; 5: 60–7.PubMedGoogle Scholar
  4. 4.
    Santoro GM, Bisi G, Sciagrà R, Leoncini M, Fazzini PF, Meldolesi U. Single photon emission computed tomography with technetium-99m hexakis 2-methoxyisobutyl isonitrile in acute myocardial infarction before and after thrombolytic treatment: assessment of salvaged myocardium and prediction of late functional recovery. J Am Coll Cardiol 1990; 15: 301–14.PubMedCrossRefGoogle Scholar
  5. 5.
    Kayden DS, Mattera JA, Zaret BL, Wackers FJ. Demonstration of reperfusion after thrombolysis with technetium-99m isonitrile myocardial imaging. J Nucl Med 1988; 29: 1865–7.PubMedGoogle Scholar
  6. 6.
    Wackers FJ, Gibbons RJ, Verani MS et al. Serial quantitative planar technetium-99m isonitrile imaging in acute myocardial infarction: efficacy for noninvasive assessment of thrombolytic therapy. J Am Coll Cardiol 1989; 14: 861–73.PubMedCrossRefGoogle Scholar
  7. 7.
    Hendel RC, McSherry B, Karimeddini M, Leppo JA. Diagnostic value of a new myocardial perfusion agent, teboroxime (SQ 30,217), utilizing a rapid planar imaging protocol: preliminary results. J Am Coll Cardiol 1990; 16: 855–61.PubMedCrossRefGoogle Scholar
  8. 8.
    Iskandrian AS, Heo J, Nguyen T, Mercuro J. Myocardial imaging with Tc-99m teboroxime: technique and initial results. Am Heart J 1991; 121: 889–94.PubMedCrossRefGoogle Scholar
  9. 9.
    Gould KL, Goldstein RA, Mullani NA et al. Noninvasive assessment of coronary stenoses by myocardial perfusion imaging during pharmacologic coronary vasodilatation. VIII. Clinical feasibility of positron cardiac imaging without a cyclotron using generator-produced rubidium-82. J Am Coll Cardiol 1986; 7: 775–89.PubMedCrossRefGoogle Scholar
  10. 10.
    Williams KA, Ryan JW, Resnekov L et al. Planar positron imaging of rubidium-82 for myocardial infarction: a comparison with thallium-201 and regional wall motion. Am Heart J 1989; 118: 601–10.PubMedCrossRefGoogle Scholar
  11. 11.
    Krivokapich J, Smith GT, Huang SC et al. N-13 ammonia myocardial imaging at rest and with exercise in normal volunteers. Quantification of absolute myocardial perfusion with dynamic positron emission tomography. Circulation 1989; 30: 1328–37.CrossRefGoogle Scholar
  12. 12.
    Bergmann SR, Herrero P, Markham J, Weinheimer CJ, Walsh MN. Noninvasive quantitation of myocardial blood flow in human subjects with oxygen-15-labeled water and positron emission tomography. J Am Coll Cardiol 1989; 14: 639–52.PubMedCrossRefGoogle Scholar
  13. 13.
    Walsh MN, Geltman EM, Steele RL et al. Augmented myocardial perfusion reserve after coronary angioplasty quantified by positron emission tomography with oxygen-15 labeled water. J Am Coll Cardiol 1990; 15: 119–27.PubMedCrossRefGoogle Scholar
  14. 14.
    Shelton ME, Green MA, Mathias CJ, Welch MJ, Bergmann SR. Assessment of regional myocardial and renal blood flow using copper-PTSM and positron emission tomography. Circulation 1990; 82: 990–7.PubMedCrossRefGoogle Scholar
  15. 15.
    Willerson JT, Parkey RW, Stokely EM et al. Infarct sizing with technetium-99m stannous pyrophosphate scintigraphy in dogs and man; relationship between scintigraphic and precordial mapping estimates of infarct size in patients. Cardiovasc Res 1977; 11: 291–8.PubMedCrossRefGoogle Scholar
  16. 16.
    Stokely EM, Buja LM, Lewis SE et al. Measurement of acute myocardial infarcts in dogs with 99m-Tc-stannous pyrophosphate scintigrams. J Nucl Med 1976; 17: 1–5PubMedGoogle Scholar
  17. 17.
    Braat SH, Brugada P, De Zwaan C, Coenegracht JM, Wellens HJJ. Value of electrocardiogram in diagnosing right ventricular involvement in patients with an acute inferior wall myocardial infarction. Br Heart J 1983; 49: 368–72.PubMedCrossRefGoogle Scholar
  18. 18.
    Olson HG, Lyons KP, Butman S, Piters KM. Validation of technetium-99m stannous pyrophosphate myocardial scintigraphy for diagnosing acute myocardial infarction more than 48 hours old when serum creatine kinase-MB has returned to normal. Am J Cardiol 1983; 52: 245–51.PubMedCrossRefGoogle Scholar
  19. 19.
    Hashimoto T, Kambara H, Fudo T et al. Early estimation of acute myocardial infarct size soon after coronary reperfusion using emission computed tomography with technetium-99m pyrophosphate. Am J Cardiol 1987; 60: 952–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Takeda K, LaFrance ND, Weisman HF, Wagner HN, Becker LC. Comparison of indium-111 antimyosin antibody and technetium-99m pyrophosphate localization in reperfused and nonreperfused myocardial infarction. J Am Coll Cardiol 1991; 17: 519–26.PubMedCrossRefGoogle Scholar
  21. 21.
    Khaw BA, Beller GA, Haber E, Smith TW. Localization of cardiac myosin-specific antibody in myocardial infarction. J Clin Invest 1976; 58: 439–46.PubMedCrossRefGoogle Scholar
  22. 22.
    Antunes ML, Seldin DW, Wall RM, Johnson LL. Measurement of acute Q-wave myocardial infarct size with single photon emission computed tomography imaging of indium-111 antimyosin. Am J Cardiol 1989; 63: 777–83.PubMedCrossRefGoogle Scholar
  23. 23.
    Johnson LL, Lerrick KS, Coromilas J et al. Measurement of infarct size and percentage myocardium infarcted in a dog preparation with single photon emission computed tomography, thallium-201, and indium 111-monoclonal antimyosin Fab. Circulation 1987; 76:181–90.PubMedCrossRefGoogle Scholar
  24. 24.
    Johnson LL, Seldin DW, Becker LC et al. Antimyosin imaging in acute transmural myocardial infarctions: results of a multicenter clinical trial. J Am Coll Cardiol 1989; 13: 27–35PubMedCrossRefGoogle Scholar
  25. 25.
    Johnson LL, Seldin DW, Keller AM et al. Dual isotope thallium and indium antimyosin SPECT imaging to identify acute infarct patients at further ischémie risk. Circulation 1990; 81: 37–45.PubMedCrossRefGoogle Scholar
  26. 26.
    Van Vlies B, Baas J, Visser CA et al. Predictive value of indium-111 antimyosin uptake for improvement of left ventricular wall motion after thrombolysis in acute myocardial infarction. Am J Cardiol 1989; 64: 167–71.PubMedCrossRefGoogle Scholar
  27. 27.
    Carrio I, Berna L, Ballester M et al. Indium-111 antimyosin scintigraphy to assess myocardial damage in patients with suspected myocarditis and cardiac rejection. J Nucl Med 1988; 29: 1893–1900.PubMedGoogle Scholar
  28. 28.
    Ballester-Rodes M, Carrio-Gasset I, Abadal-Berini L, Obrador-Mayol D, Berna-Roqueta L, Caralps-Riera JM. Patterns of evolution of myocyte damage after human heart transplantation detected by indium-111 monoclonal antimyosin. Am J Cardiol 1988; 62: 623–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Dec GW, Palacios I, Yasuda T et al. Antimyosin antibody cardiac imaging: its role in the diagnosis of myocarditis. J Am Coll Cardiol 1990; 16: 97–104.PubMedCrossRefGoogle Scholar
  30. 30.
    Ter-Pogossian MM, Klein MM, Markham J, Roberts R, Sobel BE. Regional assessment of yocardial metabolic integrity in vivo by positron-emission tomography with C-11-labeled palmitate. Circulation 1980; 61: 242–55.PubMedCrossRefGoogle Scholar
  31. 31.
    Sochor H, Schwaiger M, Schelbert HR et al. Relationship between TI-201, Tc-99m (Sn) pyrophosphate and F-18 2-deoxyglucose uptake in ischemically injured dog myocardium. Am Heart J 1987; 114: 1066–77.PubMedCrossRefGoogle Scholar
  32. 32.
    Bergmann SR, Lerch RA, Fox KAA et al. Temporal dependence of beneficial effects of coronary thrombolysis characterized by positron tomography. Am J Med 1982; 73: 573–81.PubMedCrossRefGoogle Scholar
  33. 33.
    Brunken R, Schwaiger M, Grover-McKay M, Phelps ME, Tillisch J, Schelbert HR. Positron emission tomography detects tissue metabolic activity in myocardial segments with persistent thallium perfusion defects. J Am Coll Cardiol 1987; 10: 557–67.PubMedCrossRefGoogle Scholar
  34. 34.
    Tamaki N, Othani H, Yamashita K et al. Metabolic activity in the areas of new fill-in after thallium-201 reinjection: comparison with positron emission tomography using fluorine-18-deoxyglucose. J Nucl Med 1991; 32: 673–8.PubMedGoogle Scholar
  35. 35.
    Van der Wall EE, Den Hollander W, Heidendal GAK, Westera G, Majid PA, Roos JP. Dynamic myocardial scintigraphy with I-123 labeled free fatty acids in patients with myocardial infarction. Eur J Nucl Med 1981; 6: 383–9.PubMedGoogle Scholar
  36. 36.
    Van Eenige MJ, Visser FC, Duwel CMB, Karreman AJP, Van Lingen A, Roos JP. Comparison of 17-iodine-131 heptadecanoic acid kinetics from externally measured time-activity curves and from serial myocardial biopsies in an open-chest canine model. J Nucl Med 1988; 29:1934–42.PubMedGoogle Scholar
  37. 37.
    Visser FC, Westera G, Van Eenige MJ, Van der Wall EE, Heidendal GAK, Roos JP. Free fatty acid scintigraphy in patients with successful thrombolysis after myocardial infarction. Clin Nucl Med 1985; 10: 35–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Hansen CL, Corbett JR, Pippin JJ et al. Iodine-123 phenylpentadecanoic acid and single photon emission computed tomography in identifying left ventricular regional metabolic abnormalities in patients with coronary heart disease: comparison with thallium-201 myocardial tomography. J Am Coll Cardiol 1988; 12: 78–87.PubMedCrossRefGoogle Scholar
  39. 39.
    Ugolini V, Hansen CL, Kulkarni PV, Jansen DE, Akers MS, Corbett JR. Abnormal myocardial fatty acid metabolism in dilated cardiomyopathy detected by iodine-123 phenylpentadecanoic acid and tomographic imaging. Am J Cardiol 1988; 62: 923–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Armbrecht JJ, Buxton DB, Schelbert HR. Validation of 1-11Cacetate as a tracer for noninvasive assessment of oxidative metabolism with positron-emission tomography in normal, ischemic, postischemic, and hyperemic canine myocardium. Circulation 1990; 81: 1584–1605CrossRefGoogle Scholar
  41. 41.
    Buxton DB, Schwaiger M, Mody FV et al. Regional abnormality in oxygen consumption in reperfused myocardium assessed with 1-11C acetate and positron emission tomography. Am J Card Imaging 1990; 3: 276–87.Google Scholar
  42. 42.
    Walsh MN, Geltman EM, Brown MA et al. Noninvasive estimation of regional myocardial oxygen consumption by positron emission tomography with carbon-11 acetate in patients with myocardial infarction. J Nucl Med 1989; 30: 1798–1808.PubMedGoogle Scholar
  43. 43.
    Shelton M, Dence CS, Hwang DR, Herrero P, Walsh MN, Bergmann SR. In vivo delineation of myocardial hypoxia during coronary occlusion using fluorine-19 fluoromisonidazole and positron emission tomography: a potential approach for identification of jeopardized myocardium. J Am Coll Cardiol 1990; 16: 477–85.PubMedCrossRefGoogle Scholar
  44. 44.
    Kline RC, Swanson DP, Wieland DM et al. Myocardial imaging in man with 1-123 metaiodobenzylguanidine. J Nucl Med 1981; 22: 129–32.PubMedGoogle Scholar
  45. 45.
    Minardo JD, Tuli MM, Mock BH et al. Scintigraphic and electrophysiological evidence of canine myocardial sympathetic denervation and reinnervation produced by myocardial infarction or phenol application. Circulation 1988; 78: 1008–19.PubMedCrossRefGoogle Scholar
  46. 46.
    Dae MW, O’Connell JW, Botvinick EH et al. Scintigraphic assessment of regional cardiac adrenergic innervation. Circulation 1989; 79: 634–44.PubMedCrossRefGoogle Scholar
  47. 47.
    Stanton MS, Tuli MM, Radtke NL et al. Regional sympathetic denervation after myocardial infarction in humans detected noninvasively using I-123-metaiodobenzylguanidine. J Am Coll Cardiol 1989; 14: 1519–26.PubMedCrossRefGoogle Scholar
  48. 48.
    Henderson EB, Kahn JK, Corbett JR et al. Abnormal I-123 metaiodobenzylguanidine myocardial washout and distribution may reflect myocardial adrenergic derangement in patients with congestive cardiomyopathy. Circulation 1988; 78: 1192–9.PubMedCrossRefGoogle Scholar
  49. 49.
    Schwaiger M, Kalff V, Rosenspire K et al. Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography. Circulation 1990; 82: 457–64.PubMedCrossRefGoogle Scholar
  50. 50.
    Goldstein DS, Change PC, Eisenhofer G et al. Positron emission tomographic imaging of cardiac sympathetic innervation and function. Circulation 1990; 81: 1606–21.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 1992

Authors and Affiliations

  • Ernst E. Van Der Wall

There are no affiliations available

Personalised recommendations